Conduit Pharms Stock Price, News & Analysis

Conduit Pharmaceuticals (Nasdaq: CDT) has filed two groundbreaking patents for VTAMA® (tapinarof), including a dual active cocrystal formulation that combines the drug with a complementary substance to address both therapeutic needs and side effects in inflammatory skin conditions.

The new patents come as VTAMA® approaches its 2027 exclusivity expiration. The innovation aims to enhance patient benefits by addressing symptoms like pain and itch, while extending patent protection and expanding therapeutic applications. This development is particularly significant as tapinarof enters clinical trials for cutaneous lupus and shows promise in other inflammatory and autoimmune indications.

The strategic timing aligns with the growing anti-inflammatory therapeutics market, projected to exceed $233.6 billion by 2032. The company is actively seeking partnerships to leverage this breakthrough IP while continuing to advance its broader pipeline.

Conduit Pharmaceuticals (Nasdaq: CDT) has announced a share repurchase program authorizing the buyback of up to $1,000,000 of its outstanding common stock. The company's Board of Directors initiated this program believing the current market price doesn't reflect the stock's underlying value.

The repurchase will be executed through The Benchmark Company via open market transactions or other methods compliant with SEC Rule 10b-18. The program has no fixed expiration date and can be adjusted or terminated based on market conditions, corporate liquidity, and regulatory considerations.

CEO Dr. David Tapolczay indicated the company will use existing cash reserves for potential buybacks, while maintaining focus on upcoming pipeline milestones, including preclinical data readouts and Phase II trial initiation for AZD1656.

Conduit Pharmaceuticals (Nasdaq: CDT) has expanded its partnership with Sarborg through an additional license and use agreement to enhance the analysis of its AstraZeneca-acquired assets. The collaboration focuses on applying machine learning algorithms to analyze clinical and safety data for AZD1656, AZD5658, and AZD5904.

Under the six-month non-exclusive, non-transferable license agreement, Sarborg will conduct in-depth analysis of clinical trial data to identify missed insights, drug repurposing opportunities, and data gaps. The partnership aims to evaluate historical trial data and endpoints to identify potential therapeutic benefits in specific patient subgroups, which could optimize future clinical development strategies.

Conduit Pharmaceuticals (Nasdaq: CDT) has received USPTO approval for a composition of matter patent for its lead asset AZD1656, a Glucokinase Activator targeting autoimmune diseases including Lupus and ANCA Vasculitis. The patent grants up to 20 years of market protection in the United States.

The company now holds patent protection in three major pharmaceutical markets - US, Japan, and Australia - with pending applications in Europe and other regions. This positions Conduit for clinical development and strategic partnerships in the U.S. autoimmune disease market, projected to reach $150 billion by 2030.

The targeted conditions affect a significant population, with Lupus impacting 1.5 million Americans and ANCA Vasculitis affecting 200,000 patients annually. The composition of matter patent, classified as a 'drug substance' patent in the FDA's Orange Book, provides strong market exclusivity and protection against generic competition.

Conduit Pharmaceuticals (Nasdaq: CDT) has announced significant progress in its R&D pipeline development for three key assets: AZD1656, AZD5658, and AZD5904. The company has partnered with Charles River Laboratories for preclinical studies of glucokinase inhibitors in autoimmune diseases, focusing on lupus, with results expected in Q2 2025.

The company is designing a Phase II clinical trial for AZD1656, targeting systemic lupus erythematosus (SLE) with nephritis and ANCA-associated vasculitis (AAV). The trial will be single-center, double-blind, and placebo-controlled.

Notable developments include:

• Granted composition-of-matter patents for AZD1656 Cocrystals by Japan Patent Office and IP Australia
• Pending patent applications at USPTO and European Patent Office
• Partnership with Agility Life Sciences for developing novel solid oral-dosage forms
• Ongoing formulation optimization at Cambridge Science Park facility

Conduit Pharmaceuticals (Nasdaq: CDT) has received an extension from the Nasdaq Hearing Panel to achieve compliance with listing requirements. The company presented its compliance plan on February 11, 2025, and received written notification of the extension on March 5, 2025.

The extension requires Conduit to:

• File an application to transfer to the Nasdaq Capital Market by March 12, 2025
• Demonstrate compliance with all Nasdaq listing rules by March 31, 2025

As of February 26, 2025, the company has already regained compliance with the Minimum Bid Price rule. Following the transfer to Nasdaq Capital Market, Conduit's Market Value of Publicly Held Shares will meet the $1.0 million requirement. The company expects to demonstrate compliance with the Equity Standard of Stockholder's Equity exceeding $2.5 million by the March deadline, though this is not guaranteed.

Conduit Pharmaceuticals (Nasdaq: CDT) has completed initial milestones in Phase II of its strategic collaboration with AI and Cybernetics company, Sarborg The collaboration focuses on developing personalized dashboards to provide Conduit’s key personnel with real-time access to data related to deliverables, R&D oversight, and drug discovery. This phase has delivered a prototype AI product to Conduit’s management team, featuring user dashboards and interface mock-ups for real-time evaluation of key deliverables.

These dashboards will undergo continuous reassessment and improvement to enhance efficiency and data analysis. The collaboration aims to address challenges in the pharmaceutical sector, such as reducing human error in critical decision-making processes like clinical development and asset identification. By integrating Sarborg’s algorithmic AI and cybernetics technology, Conduit aims to improve efficiency, lower costs, and accelerate timelines, ultimately optimizing the drug development cycle.

Conduit is committed to adopting innovative solutions to stay at the forefront of its industry, reducing reliance on traditional methods, and leveraging AI-driven technology to maximize clinical decision-making efficiency alongside its Phase II clinical programs in auto-immune disorders.

Conduit Pharmaceuticals (Nasdaq: CDT) has announced a partnership with Charles River Laboratories to evaluate its lead compound AZD1656 in a pre-clinical Systemic Lupus Erythematosus (SLE) model. The collaboration aims to generate high-quality preclinical data to optimize the development pathway for autoimmune treatments, particularly focusing on SLE and Lupus Nephritis (LN).

The study will assess drug impact on disease progression, inflammatory markers, and pro-inflammatory cytokine levels to understand effects on Treg immunoregulation. By leveraging Charles River's expertise in immunology and preclinical research, Conduit aims to enhance predictability of clinical outcomes and increase efficiency of planned Phase II trials.

This strategic partnership is expected to provide essential data to inform and de-risk future clinical trials, potentially reducing development timelines and maximizing AZD1656's therapeutic potential while strengthening opportunities for out-licensing.

Conduit Pharmaceuticals (Nasdaq: CDT) has announced significant debt-related developments. The company has fully repaid its $600,000 promissory note to Nirland , which was issued on October 28, 2024, with a 12% annual interest rate and original maturity date of October 31, 2025.

Additionally, Nirland has converted approximately $1.7 million of the original $2.65 million principal amount under the Senior Secured Promissory Note into Conduit's common stock. This Senior Note, established on August 6, 2024, carries a 12% annual interest rate, payable monthly in arrears either in cash or as accrued at Nirland's discretion.

These actions reduce Conduit's debt obligations and align Nirland's interests with shareholders.